Restoring FDA Compliance and Restarting Production After a Critical Remediation Event

Executive Summary

Critical FDA remediation Program in a regulated medical technology environment after major findings related to Final Acceptance activities caused a production stop. The Program focused on restoring compliance, redesigning affected processes, remediating Device History Records, aligning suppliers, and restarting production under significant regulatory and financial pressure. The work required coordination across legal, regulatory, quality, operations, supplier, and leadership stakeholders. Outcomes included restored production, CFR Title 21 compliance, 50% improvement in quality control measures, and prevention of nearly €45M in potential losses by completing the remediation earlier than expected.

Challenge

Major FDA findings related to Final Acceptance activities had caused a production stop. The business impact was immediate, with a daily financial exposure of €1M. At the same time, the remediation could not be rushed in a way that weakened regulatory discipline, documentation quality, or long-term process control. The core challenges included: production stop caused by major FDA findings immediate financial exposure from halted production need to comply with CFR Title 21 requirements remediation of Device History Records redesign of internal Final Acceptance processes alignment of legal, regulatory, quality, operations, and supplier stakeholders supplier training and implementation of revised supplier processes preparation of evidence and documentation for compliance closure need to restore production without creating recurrence risk The Program required fast execution under pressure while maintaining the rigor expected in a regulated medical technology environment.

Role & Scope

As Program Manager, the role covered remediation governance, stakeholder coordination, regulatory alignment, process redesign, DHR remediation, supplier training, quality control improvement, internal audit preparation, FDA communication support, legal coordination, and production restart readiness. The Program involved senior leadership, legal advisors, regulatory affairs, quality assurance, operations, suppliers, documentation owners, and FDA-facing communication channels. Responsibilities included structuring the remediation Program, chairing the governance rhythm, managing decisions and escalations, and driving execution toward compliance closure and production recovery.

Approach

The Program started with an immediate response structure to assess the FDA findings, clarify the remediation scope, and align all critical stakeholders on the recovery path. Legal, regulatory, quality, and operational stakeholders were brought into a controlled governance rhythm to ensure decisions were fast, documented, and compliant. The remediation approach included: cross-functional response team setup assessment of FDA findings and root causes CFR Title 21 requirement alignment remediation strategy and milestone planning redesign of Final Acceptance processes SOP updates and additional quality checks Device History Record remediation and review supplier training and supplier process implementation internal audits and evidence preparation regulatory communication support reinspection readiness and production restart preparation Governance was central to the execution. Progress, risks, open issues, supplier readiness, documentation status, and compliance evidence were tracked through a structured cadence. The focus was to restore production quickly while strengthening the underlying process control.

Key Contributions

• Established the Program structure for a critical FDA remediation and production recovery initiative.
• Coordinated legal, regulatory, quality, operations, supplier, and leadership stakeholders under high pressure.
• Translated CFR Title 21 requirements into executable remediation workstreams.
• Redesigned Final Acceptance processes to address the major findings and reduce recurrence risk.
• Led remediation and review of Device History Records to restore documentation compliance.
• Implemented revised SOPs, additional quality checks, and stronger process controls.
• Trained suppliers and internal stakeholders on updated compliance expectations and processes.
• Prepared audit evidence, progress reporting, and readiness material for compliance closure and production restart.

Impact

• Production restored after remediation
• €45M in potential losses prevented by completing the Program earlier than expected
• €1M daily financial exposure addressed through accelerated remediation execution
• CFR Title 21 compliance achieved
• 50% improvement in quality control measures
• 0 days production downtime after remediation
• The Program restored operational control, strengthened regulatory compliance, improved Final Acceptance processes, and created a more robust quality control structure. It also reduced recurrence risk through updated procedures, supplier alignment, documentation remediation, and stronger governance.

Capabilities Demonstrated

• Program leadership
• FDA remediation
• CFR Title 21 execution
• Production recovery
• Regulatory compliance
• Crisis management
• Quality process redesign
• Device History Record remediation
• Supplier training and alignment
• Governance and execution control